Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks -- and the track record of the company behind the picks -- so individuals can make better investing decisions.
In addition to following professional banks, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 115,000 members, many of whom demonstrate better investing insight than published analysts do.
Enough top-performing CAPS investors are striking a newly bearish tone on Amedisys
Although it operates in a boring industry, with peers such as Apria Healthcare and Lincare Holdings
But recently, Citron Research -- which has reported on questionable accounting at companies such as ArthroCare
Although it stopped short of accusing Amedisys of Medicare fraud, Citron nonetheless spooked investors and stirred up memories of WellCare
To see what the very best CAPS members are saying now about Amedisys -- as well as about other winning stocks that they're picking and panning -- head on over to CAPS and have a look. Unlike analyst opinions, which are reserved for paying clients, the community research and resources in CAPS are totally free.
Further Foolishness: